Preventive Cardioprotection of Erythropoietin Against Doxorubicin-Induced Cardiomyopathy.

Xing Chen,Yongli Chen,Yanyong Bi,Naikuan Fu,Chunyan Shan,Sili Wang,Shahid Aslam,Peixian Wang,Jing Xu
DOI: https://doi.org/10.1007/s10557-007-6052-0
2007-01-01
Cardiovascular Drugs and Therapy
Abstract:Doxorubicin (DOX) is a highly effective chemotherapeutic agent related to dose-dependent cardiomyopathy. Recent evidence suggests that erythropoietin (EPO) can play a protective role in cardiovascular diseases by non-erythropoietic effects. In the present study, we tested the hypothesis that EPO may protect against DOX-induced cardiomyopathy through anti-apoptotic mechanisms both in vitro and in vivo.
What problem does this paper attempt to address?